CURE sat down with Dr. Kerry A. Rogers for an interview at the Hairy Cell Leukemia Foundation 2025 Conference, hosted in Bologna, Italy. We sat down with Dr. Kerry A. Rogers for an interview at the ...

Hairy cell leukaemia (HCL) remains an intriguing B‐cell malignancy defined by its distinctive “hairy” cytoplasmic projections and its unique pattern of bone marrow infiltration. Recent research has ...

Dr. Alessandro Gozzetti highlights fertility and reproductive health as often overlooked but vital aspects of survivorship in hairy cell leukemia. According to Dr. Alessandro Gozzetti, fertility and ...

Results from the largest report ever on young hairy cell leukemia (HCL) patients treated with standard chemotherapy — cladribine — are a mixed bag. On the one hand, a majority of the 83 patients, all ...

HCL uniformly harbors a BRAF mutation that is not present in other B-cell malignancies. Hairy cell leukemia (HCL) is an indolent B-cell lymphoproliferative disorder that responds to several highly ...

Enormous progress in the treatment of hairy cell leukemia over the last five decades has emerged as a result of organized clinical investigations. Although interferon represented one of the initial ...

Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in ...

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): ...

CLEVELAND, Ohio — Researchers at Case Western Reserve University School of Medicine and MetroHealth System have developed a ...

Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in ...